The estimated Net Worth of Capital Management Lp Conso... is at least 98.2 百万$ dollars as of 28 March 2016. Capital Conso owns over 120,000 units of Vericel Corp stock worth over 97,579,478$ and over the last 9 years Capital sold VCEL stock worth over 646,800$.
Capital has made over 1 trades of the Vericel Corp stock since 2016, according to the Form 4 filled with the SEC. Most recently Capital sold 120,000 units of VCEL stock worth 646,800$ on 28 March 2016.
The largest trade Capital's ever made was selling 120,000 units of Vericel Corp stock on 28 March 2016 worth over 646,800$. On average, Capital trades about 120,000 units every 0 days since 2016. As of 28 March 2016 Capital still owns at least 2,232,940 units of Vericel Corp stock.
You can see the complete history of Capital Conso stock trades at the bottom of the page.
Over the last 10 years, insiders at Vericel Corp have traded over 9,831,645$ worth of Vericel Corp stock and bought 890 units worth 10,297$ . The most active insiders traders include Dominick Colangelo、Gerard J Michel、Kevin F Mclaughlin. On average, Vericel Corp executives and independent directors trade stock every 17 days with the average trade being worth of 567,401$. The most recent stock trade was executed by Steven C Gilman on 4 September 2024, trading 5,000 units of VCEL stock currently worth 18,700$.
about vericel founded in 1989, vericel (formerly aastrom biosciences), is dedicated to the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. the company markets two cell therapy products in the united states, carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee and epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. vericel is also developing maci, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-t, a patient specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (dcm). to fulfill vericel’s mission of helping people with severe diseases and conditions rea
Vericel Corp executives and other stock owners filed with the SEC include: